The second phase of the Saskatchewan Biosimilars Initiative launches on February 1, 2026. Under the Biosimilars Initiative, patients receive Saskatchewan Drug Plan coverage for a biosimilar when one is available and listed on the Saskatchewan Formulary. Biosimilars offer safe, effective treatment options and support significant cost savings and long term health system sustainability. Expanding the initiative helps maintain patient access to publicly funded drug coverage.
The second phase of the Biosimilars Initiative includes four drugs listed on the Saskatchewan Formulary:
- denosumab (Prolia®);
- omalizumab (Xolair®);
- tocilizumab (Actemra®); and,
- ustekinumab (Stelara®).
For more information, visit: